216 research outputs found
When Mars Versus Venus is Not a Cliché: Gender Differences in the Neurobiology of Alzheimer’s Disease
Digital Therapeutics for Mental Health: Is Attrition the Achilles Heel?
Digit therapeutics are novel software devices that clinicians may utilize in
delivering quality mental health care and ensuring positive outcomes. However,
uptake of digital therapeutics and clinically tested software-based programs
remains low. This article presents possible reasons for attrition and low
engagement in clinical studies investigating digital therapeutics, analyses of
studies in which engagement was high, and design constructs that may encourage
user engagement. The aim is to shed light on the importance of real-world
attrition data of digital therapeutics, and important characteristics of
medical devices that have positively influenced user engagement. The findings
presented in this article will be useful to relevant stakeholders and medical
device experts tasked with addressing the gap between software medical design
and user engagement present in digital therapeutic clinical trials.Comment: 11 pages, 1 tabl
Toward Personalized Network Biomarkers in Alzheimer's Disease: Computing Individualized Genomic and Protein Crosstalk Maps
Frontal White Matter Anisotropy and Antidepressant Remission in Late-Life Depression
10.1371/journal.pone.0003267PLoS ONE39
Exercise Fails to Improve Neurocognition in Depressed Middle-Aged and Older Adults
Purpose: Although cross-sectional studies have demonstrated an association between higher levels of aerobic fitness and improved neurocognitive function, there have been relatively few interventional studies investigating this relationship, and results have been inconsistent. We assessed the effects of aerobic exercise on neurocognitive function in a randomized controlled trial of patients with major depressive disorder (MDD). Methods: Two-hundred and two sedentary men (n = 49) and women (n = 153), aged 40 yr and over and who met diagnostic criteria for MDD, were randomly assigned to the following: a) supervised exercise, b) home-based exercise, c) sertraline, or d) placebo pill. Before and after 4 months of treatment, participants completed measures of: Executive Function (Trail Making Test BA difference score, Stroop Color/Word, Ruff 2 & 7 Test, Digit Symbol), Verbal Memory (Logical Memory, Verbal Paired Associates), and Verbal Fluency/Working Memory (Animal Naming, Controlled Oral Word Association Test, Digit Span). Multivariate analyses of covariance were performed to test the effects of treatment on posttreatment neuropsychological test scores, with baseline neuropsychological test scores, age, education, and change in depression scores entered as covariates. Results: The performance of exercise participants was no better than participants receiving placebo across all neuropsychological tests. Exercise participants performed better than participants receiving sertraline on tests of executive function but not on tests of verbal memory or verbal fluency/ working memory. Conclusions: We found little evidence to support the benefits of an aerobic exercise intervention on neurocognitive performance in patients with MDD. Originally published Medicine and Science in Sport and Exercise, Vol. 40, No. 7, July 200
- …